Clinical Trial: Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07216248) titled 'Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer' on Sept. 30.

Brief Summary: The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Intervention: DRUG: relugolix + ARPI

Step 1: Continuous treatment with relugolix + ARPI

DRUG: Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI

Intermittent treatment wit...